Developing a vaccine to generate broad immunity against HIV
Combining membrane Env vaccine regimens to elicit multiple bnAb lineages and consistent cross-neutralization of HIV
This study is working on a new HIV vaccine that helps your body make stronger defenses against the virus, using a special method to boost your immune system, and it could lead to a more effective way to protect you from HIV with fewer shots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10977071 on NIH RePORTER |
What this research studies
This research focuses on creating a preventative vaccine for HIV that aims to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs). By using innovative germline targeting (GT) protocols, the study seeks to activate specific B-cell precursors in the body to enhance their ability to fight HIV. The approach involves using a new liposome platform that has shown promise in animal models, aiming to improve the efficiency of the vaccine and its ability to elicit a strong immune response with fewer doses. Patients may benefit from this research as it could lead to a more effective HIV vaccine that provides long-lasting protection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection or those who are HIV-negative but may benefit from preventive measures.
Not a fit: Patients who are already HIV-positive or those with compromised immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective HIV vaccine that significantly reduces the risk of infection.
How similar studies have performed: Previous research has shown promise in developing vaccines that elicit bnAbs, but this approach is innovative and aims to improve upon existing methods.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Zwick, Michael B — Scripps Research Institute, the
- Study coordinator: Zwick, Michael B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.